{"analyses":[{"ciLowerLimit":"0.618","ciNumSides":"TWO_SIDED","ciPctValue":"95","ciUpperLimit":"0.954","estimateComment":"The Hazard Ratio is based on a stratified Cox regression model including treatment as covariate, and histology, geographic region, and number of prior regimens for advanced STS as strata.","groupDescription":"Statistical analysis was designed to detect superiority of Arm A (eribulin) over Arm B (dacarbazine). OS was compared between the two treatment arms using a two-sided stratified log-rank test at a nominal significance level of 0.0455 (adjusted for the interim analysis). This was the primary analysis that was performed when the target number of events (\\~353 deaths) was observed.","groupIds":["OG000","OG001"],"nonInferiorityType":"SUPERIORITY_OR_OTHER_LEGACY","pValue":"=0.0169","pValueComment":"The P-value was calculated by 2-sided log-rank test as stratified by histology, geographic region, and number of prior regimens for advanced STS.","paramType":"Hazard Ratio (HR)","paramValue":"0.768","statisticalMethod":"Log Rank"}],"classes":[{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"10.9","upperLimit":"15.6","value":"13.5"},{"groupId":"OG001","lowerLimit":"9.6","upperLimit":"13.0","value":"11.5"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"228"},{"groupId":"OG001","value":"224"}],"units":"Participants"}],"description":"OS was defined as the time in months from the date of treatment start until death, regardless of cause. In the absence of confirmation of death, participants were censored either at the date that participant was last known to be alive or the date of study cut-off, whichever was earlier. Participants who died on the date of randomization had a survival time of 0.5 day. Allocation of randomization numbers were performed based upon the following stratification factors: (a) Histology (adipocytic \\[ADI\\] or leiomyosarcoma \\[LMS\\]), (b) Region (Region 1: USA and Canada; or Region 2: Western Europe, Australia, Israel; or Region 3: Eastern Europe, Latin America, and Asia), and (c) Number of prior regimens for advanced soft tissue sarcoma (STS) (2 or greater than \\[\\>\\] 2 prior regimens).","dispersionType":"95% Confidence Interval","groups":[{"description":"Eribulin mesylate at a dose of 1.4 mg/m\\^2 was administered IV as a bolus infusion over 2-5 minutes on Days 1 and 8 of every 21-day treatment cycle.","id":"OG000","title":"Arm A: Eribulin Mesylate"},{"description":"Dacarbazine at a dose of 850 mg/m\\^2, 1000 mg/m\\^2, or 1200 mg/m\\^2 (as selected by the Principal Investigator \\[PI\\] or designee prior to randomization according to the participant's clinical status) was administered as an IV infusion over 15-30 minutes (or up to 60 minutes as per institutional guidelines) on Day 1 of every 21-day treatment cycle.","id":"OG001","title":"Arm B: Dacarbazine"}],"paramType":"MEDIAN","populationDescription":"Full analysis set (FAS) (Intent-to-Treat (ITT) analysis set) included all participants who were randomized.","reportingStatus":"POSTED","timeFrame":"From date of treatment start until date of death from any cause, up to 5 years 5 months","title":"Overall Survival (OS)","type":"PRIMARY","unitOfMeasure":"Months"}